Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Advisory Committees”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources
PubMed1990

Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.

We studied 2254 persons receiving HLA-identical sibling bone marrow transplants for acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) in first remission, or chronic myelogenous leukemia (CML) in first chronic phase to determine whether graft-versus-leukemia (GvL) reactions are important in preventing leukemia recurrence after bone marrow transplantation. Four groups were investigated; recipients of non-T-cell depleted allografts without graft-versus-host disease (GvHD), recipients of non-T-cell depleted allografts with GvHD, recipients of T-cell depleted allografts, and recipients of genetically identical twin transplants compared with recipients of non-T-cell depleted allografts without GvHD, Decreased relapse was observed in recipients of non-T-cell depleted allografts with acute (relative risk 0.68, P = 0.03), chronic (relative risk, 0.43, P = 0.01), and both acute and chronic GvHD (relative risk 0.33, P = 0.0001). These data support an anti-leukemia effect of GvHD. AML patients receiving identical twin transplants had an increased probability of relapse (relative risk 2.58, P = 0.008) compared to allograft recipients without GvHD supporting an anti-leukemia effect of allografts independent of GvHD. CML patients receiving T-cell depleted transplants without GvHD had a higher probability of relapse (relative risk 6.91, P = 0.0001) than recipients of non-T-cell depleted allografts without GvHD. These data support an antileukemia effect independent of GvHD altered by T-cell depletion. These results indicate that much of the anti-leukemia effect of bone marrow transplants is related to immune factors rather than high-dose chemotherapy and/or radiation.

Bone Marrow Transplantation↗
PubMed1989

Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update. The Ad Hoc Advisory Committee on Peritonitis Management.

In conclusion, the recommendations provided in this document represent a distillation of various experiences, as well as data obtained from published studies. It is hoped that this compilation will provide a basis upon which future developments and advances can be made in the therapeutic approach to CAPD associated peritonitis. Paramount among these will be the development of rapid and accurate diagnostic techniques and efficacious antibiotic regimens using precisely derived dosing recommendations that minimize toxicity. Insights into catheter management should be developed, particularly as they pertain to exit and tunnel infections. The optimal interval before catheter reinsertion can be safely performed must be defined. Lastly, improvement in catheter design and materials should be sought.

Anti-Bacterial Agents↗
PubMed1989

Autologous bone marrow transplants: different indications in Europe and North America. Advisory Committee of the International Autologous Bone Marrow Transplant Registry (ABMTR).

The International Autologous Bone Marrow Transplant Registry surveyed activity at 112 centres worldwide. Transplants increased from 265 in 1981 to over 1200 in 1987. Diseases most frequently treated by autotransplantation included non-Hodgkin lymphoma (22%), acute myelogenous leukaemia (19%), acute lymphoblastic leukaemia (15%), Hodgkin disease (15%), and neuroblastoma (5%). There were striking differences in the use of autotransplants between North America and Europe. Autotransplants for lymphomas and solid tumours comprised 94% of North American Autotransplants but only 41% of those in Europe. In contrast, leukaemia was the indication in 59% of Europeans but only 6% of North Americans. 65% of leukaemia autotransplants in Europe were done in first remission compared with 8% in North America. There were also differences in age and types of lymphoma autotransplanted--Burkitt and lymphoblastic lymphoma in young persons in Europe, versus large-cell lymphomas in older persons in North America.

Age Factors↗